Louis Preston Garrison
#150,357
Most Influential Person Now
American health economist
Louis Preston Garrison's AcademicInfluence.com Rankings
Download Badge
Economics
Why Is Louis Preston Garrison Influential?
(Suggest an Edit or Addition)According to Wikipedia, Louis Preston Garrison Jr. is an American health economist who has made significant contributions to pharmacoeconomics, pharmacogenomics and personalized medicine, regulatory benefit-risk analysis, insurance, pricing, reimbursement and risk-sharing agreements. He also made numerous contributions on the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer. Garrison has published over a hundred manuscripts in peer-reviewed journals and contributed to several book chapters.
Louis Preston Garrison's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The quality of life of patients with end-stage renal disease. (1985) (760)
- Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. (2007) (566)
- Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. (2010) (265)
- Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. (2018) (253)
- Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. (2013) (228)
- Donor availability as the primary determinant of the future of heart transplantation. (1986) (188)
- Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. (2009) (143)
- Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. (2012) (134)
- Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. (2010) (131)
- An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. (2018) (112)
- Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer (2007) (111)
- A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. (2018) (100)
- Can’t Get No Satisfaction? Will Pay for Performance Help? (2012) (99)
- The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. (2009) (91)
- Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. (2010) (86)
- A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]. (2018) (84)
- Global eradication of measles: an epidemiologic and economic evaluation. (2011) (84)
- A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice (2010) (84)
- Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. (2007) (82)
- Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. (2018) (77)
- Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS (1996) (73)
- Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. (2017) (73)
- Interspecialty Variation in Office-Based Care (1984) (71)
- The Use, Safety and Cost of Bariatric Surgery Before and After Medicare's National Coverage Decision (2011) (70)
- Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. (2006) (66)
- Performance-Based Risk-Sharing Arrangements: An Updated International Review (2017) (65)
- Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda (2009) (64)
- Cost-Effectiveness of Repeat Medical Procedures (1997) (59)
- The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. (2013) (56)
- Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold. (2019) (54)
- The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. (2009) (54)
- Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity (2014) (53)
- A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile (1997) (53)
- The drug budget silo mentality in Europe: an overview. (2003) (52)
- Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. (2015) (51)
- The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group. (1997) (51)
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis (2013) (51)
- Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment (2011) (51)
- Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. (2009) (49)
- Cost Effectiveness of a Pharmacy-Only Refill Program in a Large Urban HIV/AIDS Clinic in Uganda (2011) (48)
- Economic incentives for evidence generation: promoting an efficient path to personalized medicine. (2013) (48)
- The Economics of Personalized Medicine: A Model of Incentives for Value Creation and Capture (2007) (46)
- Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers (2014) (46)
- Differential pricing of new pharmaceuticals in lower income European countries (2013) (45)
- Examining the BMI-mortality relationship using fractional polynomials (2011) (44)
- The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). (2012) (44)
- Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. (2006) (44)
- Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]. (2018) (44)
- Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle. (2010) (43)
- Design, implementation, and first-year outcomes of a value-based drug formulary. (2015) (42)
- Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics (2017) (41)
- Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. (2020) (40)
- Estimating the costs of induced abortion in Uganda: A model-based analysis (2011) (40)
- Estimating the Effect of Changes in Body Mass Index on Health State Preferences (2012) (37)
- Can and should value-based pricing be applied to molecular diagnostics? (2013) (37)
- Scheduling of measles vaccination in low-income countries: projections of a dynamic model. (2009) (36)
- Disease Control Priorities, Third Edition (Volume 6): Major Infectious Diseases (2017) (36)
- Preference values associated with stage III colon cancer and adjuvant chemotherapy (2010) (35)
- The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems (2019) (34)
- European Union Pharmaceutical Markets: A Case for Differential Pricing? (2015) (34)
- Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. (2011) (33)
- Health technology assessment in low‐ and middle‐income countries: a landscape assessment (2016) (33)
- Potential Cost-Effectiveness of Universal Access to Modern Contraceptives in Uganda (2012) (32)
- A Review of Public Policy Issues in Promoting the Development and Commercialization of Pharmacogenomic Applications: Challenges and Implications (2008) (32)
- Estimates of physician requirements for 1990 for the specialties of neurology, anesthesiology, nuclear medicine, pathology, physical medicine and rehabilitation, and radiology. A further application of the GMENAC methodology. (1983) (31)
- How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. (2011) (30)
- Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US (2015) (29)
- Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis (2009) (29)
- Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value (2016) (28)
- Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status (2013) (28)
- Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. (2011) (27)
- HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies (2020) (26)
- Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score (2011) (26)
- Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview. (2016) (23)
- Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A (2020) (23)
- The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable. (2003) (23)
- Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. (2011) (23)
- Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. (2006) (22)
- The cost offsets and cost–effectiveness associated with pegylated drugs: a review of the literature (2012) (22)
- Prioritization in Comparative Effectiveness Research: The CANCERGEN Experience (2012) (22)
- The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review (2012) (21)
- Paying for personalized care: Cancer biomarkers and comparative effectiveness (2012) (21)
- Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States (2012) (21)
- Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned (2013) (21)
- Patient characteristics and medical care costs associated with hypertriglyceridemia. (2011) (20)
- Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. (2019) (20)
- The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. (2015) (19)
- Strategic Use of Pharmacoeconomic Research in Early Drug Development and Global Pricing (1993) (19)
- Systematic review of comparative effectiveness data for oncology orphan drugs. (2012) (19)
- A review of data needed to parameterize a dynamic model of measles in developing countries (2010) (17)
- Costs of integrating cervical cancer screening at an HIV clinic in Kenya (2017) (17)
- Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study (2018) (17)
- BMI Trajectories Among the Severely Obese: Results From an Electronic Medical Record Population (2012) (17)
- Universal health coverage--big thinking versus big data. (2013) (16)
- Cost containment and incentives for technology. (1986) (16)
- Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support. (2020) (16)
- Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message. (2009) (16)
- The implications of external price referencing on pharmaceutical list prices in Europe (2018) (16)
- The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. (2019) (16)
- Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost–Utility Analysis (2016) (15)
- Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. (2003) (15)
- Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective (2020) (15)
- Insurance coverage for genomic tests (2018) (15)
- The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response (2011) (15)
- A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine. (2019) (15)
- Expanding the Evidence Base in Transplantation: The Complementary Roles of Randomized Controlled Trials and Outcomes Research (2008) (14)
- The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States (2015) (14)
- Personalized Medicine: Pricing and Reimbursement Policies as a Potential Barrier to Development and Adoption, Economics of (2014) (14)
- A flexible approach to evidentiary standards for comparative effectiveness research. (2010) (14)
- Estimating the Cost of Illness of Giant Cell Arteritis in the United States (2017) (13)
- International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. (2016) (13)
- Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. (2019) (13)
- A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. (2008) (13)
- The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting (2017) (13)
- Using the Analytic Hierarchy Process for Prioritizing Imaging Tests in Diagnosis of Suspected Appendicitis. (2017) (13)
- Effects of arginine-based immunonutrition on inpatient total costs and hospitalization outcomes for patients undergoing colorectal surgery. (2017) (13)
- The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States (2017) (12)
- Regulatory Benefit-Risk Assessment and Comparative Effectiveness Research (2012) (12)
- Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. (2021) (12)
- Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting (2011) (12)
- Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. (2006) (11)
- A Framework for Assessing the Economic Value of Pharmacovigilance in Low- and Middle-Income Countries (2014) (11)
- Retrospective outcomes studies for orphan diseases: challenges and opportunities (2012) (11)
- Cost and Health Care Utilization Implications of Bariatric Surgery Versus Intensive Lifestyle and Medical Intervention for Type 2 Diabetes (2017) (11)
- Applying quantitative benefit-risk analysis to aid regulatory decision making in diagnostic imaging: methods, challenges, and opportunities. (2014) (10)
- The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? (2012) (10)
- Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda (2017) (10)
- Post-Exposure Influenza Prophylaxis with Oseltamivir (2012) (10)
- Innovation in diagnostic imaging services: assessing the potential for value-based reimbursement. (2011) (10)
- Assessment of the effectiveness of supply-side cost-containment measures. (1992) (9)
- The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach (2015) (9)
- Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya (2019) (9)
- Value assessment in precision cancer medicine (2017) (9)
- Resource utilization and costs associated with the diagnostic evaluation of nonrefluxing primary hydronephrosis in infants. (2014) (9)
- The supply of and requirements for diagnostic and therapeutic radiologists. (1984) (8)
- Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya (2017) (8)
- Prevalence of and Comorbid Health Conditions Associated With Pediatric Prescription Opioid Use in the US (2017) (8)
- Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention. (2019) (8)
- Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer (2010) (8)
- Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework. (2019) (8)
- Data Governance Arrangements for Real-World Evidence (2015) (8)
- The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification. (2015) (8)
- Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts (2010) (8)
- Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach. (2013) (7)
- Challenges and Opportunities for Improving Benefit-Risk Assessment of Pharmaceuticals from an Economic Perspective (2008) (7)
- Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic (2021) (7)
- How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. (2019) (7)
- PHP146 Current Status and Trends in Performance-Based Schemes Between Health Care Payers and Manufacturers (2011) (7)
- Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. (2017) (7)
- The Expanding Value Footprint of Oncology Treatments. (2014) (7)
- Do cancer treatments have option value? Real-world evidence from metastatic melanoma. (2019) (7)
- The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis. (2022) (7)
- Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). (2015) (7)
- Estimating physician requirements for neurology (1984) (7)
- Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? (2022) (7)
- The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment (2010) (7)
- The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States. (2009) (6)
- Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer (2019) (6)
- Using Certification to Promote Uptake of Real-World Evidence by Payers. (2016) (6)
- Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. (2021) (6)
- Toward a Framework for Benefit-Risk Assessment in Diagnostic Imaging: Identifying Scenario-specific Criteria. (2017) (6)
- Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? (2021) (6)
- Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders (2016) (6)
- Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years. (2013) (5)
- Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy (2012) (5)
- Will Pharmacogenomics Disrupt the U.S. Health Care System? No (2009) (5)
- Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. (2013) (5)
- The Future of Global Health Procurement: Issues around Pricing Transparency (2019) (5)
- Is the world ready for gene therapy? (2022) (5)
- The use of rehabilitation services by patients with chronic renal failure: results from the National Kidney Dialysis and Kidney Transplantation Study. (1983) (5)
- Value-Based Pricing in Latin America: How Far Away Are We? (2018) (5)
- Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting (2011) (5)
- Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. (2017) (5)
- Competing biomedical HIV prevention strategies: potential cost‐effectiveness of HIV vaccines and PrEP in Seattle, WA (2019) (5)
- Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women (2020) (5)
- A proposed approach for quantitative benefit‐risk assessment in diagnostic radiology guideline development: the American College of Radiology Appropriateness Criteria Example (2017) (5)
- PCN7 THE COST-EFFECTIVENESS OF CAPECITABINE AS ADJUVANT ORAL CHEMOTHERAPY FOR DUKE'S C COLON CANCER (2005) (5)
- Economic Evaluation of Measles Eradication Study : Results for Six Countries and by Income Groups Prepared for : World Health Organization (2010) (4)
- Determinants of specialist physician ambulatory visits: a neurology example (2019) (4)
- HEALTH TECHNOLOGY ASSESSMENT OF COMPLEMENTARY DIAGNOSTICS: ISSUES, OPTIONS, AND OPPORTUNITIES (2016) (4)
- IN4 ECONOMIC EVALUATION OF INFLUENZA PANDEMIC MITIGATION STRATEGIES IN THE US USING A STOCHASTIC MICROSIMULATION INFLUENZA MODEL (2007) (4)
- Projecting the potential impact of the Cap-Score™ on clinical pregnancy, live births, and medical costs in couples with unexplained infertility (2017) (4)
- Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial (2021) (4)
- Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis (2018) (4)
- Amortization of Gene Replacement Therapies: A Health Policy Analysis Exploring a Mechanism for Mitigating Budget Impact of High-Cost Treatments (2021) (4)
- Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer. (2014) (4)
- PSY29 MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES (2010) (4)
- Sentinel site active surveillance of safety of first‐line antiretroviral medicines in Namibia (2016) (4)
- Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies (2014) (4)
- Cost-Effectiveness of Strategies for the Diagnosis and Treatment of Febrile Illness in Children (2017) (4)
- Defining and Managing High-Priced Cures: Healthcare Payers' Opinions. (2019) (4)
- Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients. (2017) (3)
- Medicaid, the uninsured, and national health spending: Federal policy implications (1990) (3)
- Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. (2019) (3)
- Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. (2011) (3)
- Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis (2021) (3)
- Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part II: A Societal Perspective (2008) (3)
- Estimating physician requirements for neurology (1985) (3)
- Economic Issues and Genomic Medicine (2010) (3)
- Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications (2022) (2)
- Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data (2021) (2)
- PHARMACOECONOMICS AND DRUG PRICING (2013) (2)
- CHAPTER 36 – Economic Issues and Genomic Medicine (2009) (2)
- Manpower requirements in ophthalmology. (1981) (2)
- Cost-Effectiveness Analysis of a Partially Effective Hiv Vaccine In San Francisco (2015) (2)
- Abstract LB-257: Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis (2018) (2)
- Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT Recommendations. (2021) (2)
- Real-world evidence for option value in metastatic melanoma. (2021) (2)
- PHP64 LINKING PAYMENT AND HEALTH OUTCOMES: A SYSTEMATIC REVIEW AND TAXONOMY OF PERFORMANCE-BASED HEALTH OUTCOMES AGREEMENTS BETWEEN HEALTH CARE PAYERS AND MANUFACTURERS (2009) (2)
- Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. (2011) (2)
- A review of economic issues for gene‐targeted therapies: Value, affordability, and access (2023) (2)
- Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries. (2010) (2)
- Diagnostic Imaging, Economic Issues in (2014) (2)
- Findings related to assessing value for private US health plans (2010) (2)
- Outcomes Assessment in Cancer: Invited Paper D Industry perspective regarding outcomes research in oncology (2004) (2)
- Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting? (2019) (2)
- Data Investigation of Bariatric Surgery Outcome and Economic Savings (2010) (1)
- The Amortization of Funding Gene Therapies: Making the 'Intangibles' Tangible for Patients (2021) (1)
- Results of an International Expert Task Force on a Health Technology Assessment Framework for Personalized Medicine in Cancer (2015) (1)
- PRM34 Estimating Markov Chain Transition Matrices in Limited Data Samples: A Monte Carlo Experiment (2012) (1)
- Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing. (2020) (1)
- OM4 LONG-TERM COST-EFFECTIVENESS OF A DIABETES RISK SCORE IN CLINICAL PRACTICE (2008) (1)
- Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. (2021) (1)
- Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. (2021) (1)
- Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States. (2012) (1)
- The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer (2021) (1)
- PIN33 A DYNAMIC MODEL FOR ASSESSING THE IMPACT OF EMERGING VACCINE TECHNOLOGIES ON MEASLES DISEASE BURDEN IN DEVELOPING COUNTRIES (2008) (1)
- Incentivizing Value In Managed Care Drug Formularies: Design, Implementation, And First-Year Outcomes Of A Value-Based Formulary (2014) (1)
- Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios (2016) (1)
- Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation. (2018) (1)
- PCN91 The Cost-Effectiveness of Trastuzumab Over the Product Life Cycle in Portugal: A Dynamic and Societal Perspective (2012) (1)
- PCV51 Health Utilities among Patients with Obstructive Hypertrophic Cardiomyopathy (oHCM): An Analysis of Patient Health-Related Quality of Life in the EXPLORER-HCM Trial (2021) (1)
- Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumors with everolimus versus sunitinib in the United States. (2012) (1)
- THU0511 Estimating the Burden of Illness of Fibromyalgia in Taiwan (2013) (1)
- Estimating the potential economic value of trastuzumab in breast cancer from 2000–2020 in five European countries (2008) (1)
- HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL (2018) (1)
- A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. (2022) (1)
- Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? (2012) (1)
- Large-Database Research: Complement to Randomized Trials? (1998) (1)
- Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of “Failed” R&D Efforts (2022) (0)
- PMS35 The Cost-Effectiveness of Pegloticase in the Treatment of Refractory Chronic Gout (2012) (0)
- PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER (2006) (0)
- PCN35 "NET HEALTH BENEFIT” - ASCO VS. I.C.E.R. VALUE FRAMEWORKS: ARE WE TALKING ABOUT THE SAME THING? (2019) (0)
- PMD24 GLYCOSYLATED HEMOGLOBIN OR FASTING GLUCOSE TESTING FOR SCREENING DIABETES IN COLOMBIA: A COST-EFFECTIVENESS ANALYSIS (2011) (0)
- Original article Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis (2013) (0)
- AC3 - DISCORDANT DESIGNATIONS OF BREAKTHROUGH DRUG INNOVATION: FRANCE VERSUS THE UNITED STATES (2018) (0)
- Precision Heor: Using Big Data to Develop a Personalized Modeling Framework (2016) (0)
- Estimating The Societal Costs Associated With Glp-1ras In The United States For The Treatment of Type 2 Diabetes (2016) (0)
- An Economic Analysis Of Workplace Screening For Obstructive Sleep Apnea (2014) (0)
- PSY78 ESTIMATING THE BMI-MORTALITY RELATION USING FRACTIONAL POLYNOMIALS (2011) (0)
- PNS95 INTERNATIONAL REFERENCE PRICING: ACCEPTANCE AND AVOIDANCE BEHAVIORS AFFECTING PATIENT ACCESS AND INNOVATION IN U.S. AND BEYOND (2020) (0)
- PIN9 THE WORKFORCE AND COST IMPLICATIONS OF SUBSTITUTING NURSES AND PHARMACISTS FOR DOCTORS IN THE FOLLOW-UP OF PATIENTS WITH AIDS ON ANTIRETROVIRALTHERAPY IN UGANDA (2008) (0)
- Health plan budget impact of introducing everolimus for treatment of advanced progressive pancreatic neuroendocrine tumors in the United States. (2012) (0)
- CN2 ECONOMIC EVALUATION OF EGFR-GUIDEDTREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER (2008) (0)
- PIN21 Cost-Effectiveness of Ceftazidime-Avibactam for Gram-Negative Infections with Limited Treatment Options in China (2020) (0)
- When is Health Economics and outcomes research evidence important to U.S. payers (2015) (0)
- TOWARD A BROADER VALUE FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT: EXPANDED COST-EFFECTIVENESS ANALYSIS (2016) (0)
- Using Latent Class Probability Estimation And Residual Inclusion To Address Confounding In Medication Adherence Modeling (2013) (0)
- PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES (2011) (0)
- Personalized Health Care in France, Germany and the United Kingdom: Are Health Technology Assessment Agencies Ready? (2013) (0)
- PCV56 THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY (2007) (0)
- VA3 GLOBAL MEASLES ERADICATION: COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020–2049 (2009) (0)
- Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison (2022) (0)
- Potential impact of the Cap-Score test™ on clinical pregnancy and medical costs in couples with unexplained infertility (2016) (0)
- Assessing The Likely Cost-Utility Of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin As Induction Therapy For High-Risk Kidney Transplant Recipients (2014) (0)
- PCV44 CHANGING COST-EFFECTIVENESS EARLY IN THE PRODUCT LIFE CYCLE: THE EXAMPLE OF CLOPIDOGREL BISULFATE (2011) (0)
- ' s response to reviews Title : Estimating the BMI-Mortality Relationship : A New Approach (2011) (0)
- PIN1: IMPACT OF INFLUENZA AND TREATMENT WITH OSELTAMIVIR ON INDIVIDUALS' DAILY ACTIVITIES AND RETURN TO NORMAL ACTIVITY (2001) (0)
- Assessment of the effectiveness of supply-side cost-containment measures (1992) (0)
- The impact of accreditation-based coverage decisions on the safety and cost of bariatric surgery (2010) (0)
- PCN35 SYSTEMATIC REVIEW OF THE IMPACT OF CHEMOTHERAPY ON PATIENT REPORTED OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG CANCER (2009) (0)
- Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency. (2022) (0)
- Sentinel site active Surveillance of the safety of first-line Antiretroviral medicines in Namibia (2015) (0)
- Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT) (2023) (0)
- Background paper on cataract surgery and physician payment under the Medicare program (1985) (0)
- PCN227 – The Expanding Value Footprint of Oncology Treatments (2014) (0)
- P01.102 Cost effectiveness of treating glioblastoma patients age 65 years or older with Tumor Treating Fields plus Temozolomide versus Temozolomide alone (2018) (0)
- PROJECTING THE COST, UTILIZATION, AND PATIENT CARE IMPACT OF PRESCRIBING EXTENDED RELEASE NON- ABUSE-DETERRENT OPIOIDS TO CHRONIC PAIN PATIENTS (2016) (0)
- PCN12 HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS (2010) (0)
- CRT-171 The Clinical and Cost Burden of Coronary Calcification: An Economic Model to Address Under-reporting and Misclassification (2015) (0)
- PHP16 IMPROVING HEALTH TECHNOLOGY APPRAISAL AND DECISION-MAKING: WHAT HAS THE BRITISH PARLIAMENT'S INQUIRY OF NICE TAUGHT US? (2008) (0)
- Abstract P238: The Economic Burden of Hypertriglyceridemia (2011) (0)
- PHP35 CHARACTERIZING PHARMACY AND MEDICAL CLAIMS FOR A PRIVATE INSURANCE POLYPHARMACY POPULATION (2008) (0)
- PHP97 Identifying Modeling Factors Influencing Coverage Decisions by Nice in 10 Single Technology Appraisals (STA) of Expensive Drugs (2012) (0)
- Assessing the Potential Cost-Effectiveness of Alternative Methods to Screen for Cervical Cancer Among HIV-Positive Women in Kenya (2014) (0)
- The lifetime economic burden of inaccurate HER2 testing: Comparing false positive and false negative HER2+ early breast cancer patients in the United States. (2013) (0)
- Heterogeneity in Preferences for Medical Male Circumcision Services: A Discrete Choice Experiment Among Uncircumcised Men In Fishing Communities in Uganda (2018) (0)
- RW2 Real-World Evidence of Option Value in Metastatic Melanoma (2021) (0)
- (237) Patterns in the use of prescription opioids among children: persistence and total daily dosage of short- and long-acting opioids. (2016) (0)
- Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast] (2022) (0)
- Authors’ Reply to Curto and Garattini: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers” (2014) (0)
- VA3 A GLOBAL COST-EFFECTIVENESS EVALUATION OF THE IMPACT OF POTENTIAL INNOVATIONS IN MEASLES VACCINATION (2009) (0)
- SMARTPHONE-ENHANCED RAPID INFLUENZA TESTS: A COST-EFFECTIVENESS ANALYSIS (2016) (0)
- Assessing the Cost-effectiveness of a Hypothetical Disease-Modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease. (2022) (0)
- Health Policy and Economic Issues in Biotechnology and Personalized Medicine (2016) (0)
- Health Policy and Economic Issues in Biotechnology and Pharmacogenetics (2007) (0)
- PCN57 A MULTI-STAKEHOLDER PERSPECTIVE ON THE CHALLENGES IN DEMONSTRATING THE LONG-TERM BENEFIT OF CANCER IMMUNOTHERAPY (2019) (0)
- (232) Prevalence of and comorbid health conditions associated with pediatric prescription opioid use in the US. (2016) (0)
- EC2 Modeling Approaches to Estimate Realized Real Option Value of Ipilimumab in Metastatic Melanoma (2021) (0)
- Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need (2022) (0)
- HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE (2018) (0)
- Toward a broader concept of societal value: family spillovers in Alzheimer's disease (2021) (0)
- Data Governance For Real-World Evidence: Cross-Country Differences And Recommendations For A Governance Framework (2016) (0)
- I3. Pharmacoeconomic evaluations: a pharmaceutical company's perspective (1996) (0)
- Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study (2018) (0)
- PR3 PREFERENCE VALUES FOR HEALTH STATES ASSOCIATED WITH COLON CANCER AND ITS TREATMENT (2007) (0)
- PHP10 ASSESSING PAYER AND EMPLOYER PERSPECTIVES RELATED TO VALUE IN HEALTH CARE (2007) (0)
- THU0347 Estimating the Cost of Illness of Giant Cell Arteritis (2015) (0)
- International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments. (2022) (0)
- Bariatric Outcomes and Obesity Modeling: Study Meeting (2010) (0)
- PDB31 Targeted Cost Saving Strategies in Diabetes Prevention Using Risk Stratification (2012) (0)
- Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer (2022) (0)
- Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part I: Issues & Recommendations (2008) (0)
- PCN82 RESEARCH PRIORITIZATION FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS (2010) (0)
- Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer. (2022) (0)
- Comparing the projected cost per HbA1c reduction of exenatide QW versus liraglutide 1.8 mg for the treatment of type 2 diabetes mellitus using alternate data sources (2014) (0)
- Practices for Measuring Drug Costs in Cost-Effectiveness Analyses : A Societal Perspective : The ISPOR Drug Cost Task Force Report — Part (2010) (0)
- Development of a Sleep Apnea-Specific Health State Utility Algorithm. (2020) (0)
- Estimating The Cost Of Illness Of Giant Cell Arteritis (2015) (0)
- What Drives Private Investment In Health Economics And Outcomes Research (2014) (0)
- Quantification Of Benefits And Risks In Medical Imaging Testing: A Literature Review (2013) (0)
- Paying for Kidneys: Reflections on Welfare Economics, Political Economy, and Market Design. (2022) (0)
- PCN65 THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+ METASTATIC BREAST CANCER (2020) (0)
- Estimating the cost-effectiveness of pregabalin for the treatment of severe Fibromyalgia in Taiwan (2013) (0)
- Assessing the potential cost-effectiveness of a smoking cessation program prior to elective surgery (2014) (0)
- PSY21 PROJECTING THE ECONOMIC OUTCOMES OF OBESITY USING A NATURAL HISTORY MODEL (2010) (0)
- 4-18-2017 The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31 st anniversary annual meeting Howard (2018) (0)
- Impact of Value-Based Benefits on Use of and Adherence to Drugs in 3 Disease Cohorts (2015) (0)
- PSY16 PROJECTING THE LIFETIME ECONOMIC COSTS OF OBESITY: A BMI TRAJECTORY-BASED MODEL (2011) (0)
- ESTIMATING THE COST TO SOCIETY FOR EXENATIDE QW AND INSULIN GLARGINE IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES (2016) (0)
- Estimating the Potential Economic Impact of Tissue Valve Replacement for Heart Valve Disease in China: Patient-Level and Population-Level Cost-Benefit Simulation Analyses. (2023) (0)
- Potential Cost-effectiveness of HIV Viral Load Sample Collection and Testing Methods in Malawi (2019) (0)
- Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study (2017) (0)
This paper list is powered by the following services:
Other Resources About Louis Preston Garrison
What Schools Are Affiliated With Louis Preston Garrison?
Louis Preston Garrison is affiliated with the following schools:
